EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness

Samantha Jacobson iD, Noah Margolese, Howard C Margolese

The Canadian Journal of Psychiatry · 2026-06 · 71 (6) · 413-419

DOI: 10.1177/07067437251386626 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 15.10.2025. Verfasst von Samantha Jacobson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Sherbrooke, Sherbrooke, Canada. Hauptthemen laut MEDLINE: Antipsychotic Agents, Weight Gain, Glucagon-Like Peptide-1 Receptor Agonists, Mental Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with severe and persistent mental illness (SPMI) experience significant metabolic side effects from antipsychotic medications, including antipsychotic-induced weight gain (AIWG). This contributes to a high prevalence of obesity, insulin resistance, and type 2 diabetes in this population, ultimately reducing life expectancy. Traditional weight management strategies, such as behavioural interventions, are often less feasible in this group. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes, have shown promise in addressing AIWG by reducing weight, improving metabolic parameters, and offering potential neuroprotective and psychiatric benefits. Evidence supports the efficacy of GLP-1RAs in managing AIWG, with studies demonstrating substantial reductions in weight and body mass index without exacerbating psychiatric symptoms. However, access to these medications remains limited due to high costs and restrictive healthcare policies. Expanding access to GLP-1RAs could bridge a critical gap in care for patients with SPMI, improving both physical and mental health outcomes. Future research should focus on evaluating long-term efficacy and cost-effectiveness, particularly in the Canadian healthcare context, to inform policy changes and optimize treatment strategies. Plain Language Summary Title Can diabetes medications help treat weight gain caused by antipsychotics?

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsWeight GainGlucagon-Like Peptide-1 Receptor AgonistsMental DisordersObesityHumans

Stichwörter der Autor:innen

adherenceantipsychoticshealthcare policyschizophrenia

Substanzen

Antipsychotic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Faculty of Medicine, University of Sherbrooke, Sherbrooke, Canada.
  • Department of Psychiatry, McGill University Health Centre, Montreal, Canada.

ORCID-Profile: Samantha Jacobson

Zitieren

APA

Jacobson, S., Margolese, N., & Margolese, H. C. (2026). GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness. The Canadian Journal of Psychiatry, 71(6), 413-419. https://doi.org/10.1177/07067437251386626

Vancouver

Jacobson S, Margolese N, Margolese HC. GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness. The Canadian Journal of Psychiatry. 2026;71(6):413-419. doi:10.1177/07067437251386626

BibTeX
@article{Jacobson2026,
  author = {Jacobson, Samantha and Margolese, Noah and Margolese, Howard C},
  title = {GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness},
  journal = {The Canadian Journal of Psychiatry},
  year = {2026},
  volume = {71},
  number = {6},
  pages = {413--419},
  doi = {10.1177/07067437251386626}
}
Kostenlos starten →